Send to

Choose Destination
Curr Med Res Opin. 2019 Mar 16:1. doi: 10.1080/03007995.2019.1596630. [Epub ahead of print]

CHINA STudy of valsartan/amlodipine fixed-dose combination-bAsed long-Term blood pressUre management in HypertenSive patients: A one-year registry (CHINA STATUS III).

Author information

a Peking University First Hospital , Beijing , China.
b Wuhan Puai Hospital , Wuhan , China.
c Zhongda Hospital Southeast University , Nanjing , China.
d Beijing Luhe Affiliated Hospital of the Capital Medical University , Beijing , China.
e The Second Affiliated Hospital of Guangzhou Medical University , Guangzhou , China.
f Fuzhou General Hospital of Nanjing Military Command , Fuzhou , China.
g Zhejiang Provincial People's Hospital , Hangzhou , China.
h First Affiliated Hospital of Harbin Medical University , Harbin , China.
i Lu Wan Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China.
j Chinese Academy of Medical Sciences, Peking Union Medical College Hospital , Beijing , China.
k Beijing hospital , Beijing , China.
l Shanghai Tenth People's Hospital , Shanghai , China.
m Shanghai Xuhui Hospital , Shanghai , China.
n The First Affiliated Hospital of Zhengzhou University , Zhengzhou , China.
o Beijing Fuxing Hospital , Beijing , China.
p Novartis Pharmaceuticals (China) , Beijing , China.



The present observational study evaluated long-term management of hypertension in patients who received treatment with valsartan and amlodipine in a single-pill combination (Val/Aml SPC) in a real-world setting in China (Chinese Clinical Trial Registry number ChiCTR1900021324).


This was a prospective, observational, multicenter, real-world registry study wherein patients with hypertension who had already received Val/Aml SPC (80/5 mg) for at least 4 weeks before study enrollment were observed for 1 year. Investigators recorded patient data every 3 months and essentially five times during the 1-year follow-up period. Effectiveness was assessed by the blood pressure (BP) control rate and average duration of treatment at the end of the study. Safety was monitored by the incidence of adverse events (AEs) and serious adverse events (SAEs).


Overall, 985 patients were enrolled (mean ± standard deviation [SD] age: 60.3 ± 11.5 years); of these, 894 were included in the full analysis set, 758 of whom completed the study. At baseline, BP was controlled (<140/90 mmHg) in 64.3% of patients on Val/Aml SPC for at least 4 weeks before enrollment. Office BP control rates significantly improved from baseline in 74.1% of patients at 1 year (P < 0.0001). Overall, 575 (87.0%) patients remained on Val/Aml SPC at 1 year (average exposure: 311.5 days). AEs were reported in 23.3% of patients. The majority of AEs were mild to moderate, and 0.6% of patients discontinued Val/Aml SPC because of SAEs.


This study provides evidence that Val/Aml SPC effectively reduced BP over the long term among Chinese hypertensive patients, with good adherence and tolerability profile, and that most hypertensive patients may benefit from this combination.


antihypertensive agents; hypertension; long-term; observational study; single-pill combination; valsartan/amlodipine

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center